UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings

Details

Introduction: Hereditary transthyretin amyloidosis (ATTRv, also referred to as hATTR; ORPHA 271861) and wild-type ATTR amyloidosis (ATTRwt; ORPHA 330001) are rare, progressive, systemic protein misfolding disorders with heterogeneous clinical presentations. ATTRv and ATTRwt amyloidosis are characterized by the deposition of amyloid fibrils in multiple organs including the heart, nerves, eyes, and soft tissues. The management of ATTR amyloidosis is complex because of its multisystemic nature and progression despite available treatment options. Morbidity is high and there are many unmet medical needs for patients. While contemporary ATTR amyloidosis cohorts are diagnosed earlier, have lower risk disease and lower mortality compared with the previous era, these advances coupled with the emergence of effective disease-modifying therapies have confounded the design of future prospective clinical trials and interpretation of historical control data.

Main body: The Amyloidosis Forum is a public-private partnership between the US Food and Drug Administration Center for Drug Evaluation and Research and the nonprofit Amyloidosis Research Consortium ( www.arci.org ). This article summarizes proceedings from the 21 June 2023 Amyloidosis Forum on advancing drug development in ATTR amyloidosis in an evolving treatment landscape. The Forum focused on elements of clinical trial design to address these challenges and discussed their strengths and weaknesses from multiple stakeholder perspectives (i.e., patient, sponsor, statistician, clinician, and regulatory authorities).

Conclusion: Given rapid evolution of natural history in ATTR amyloidosis, the utility of historical control data is limited. Leveraging contemporary real-world data is essential for clinical trial design. Evidence generation from clinical trials should address clinically relevant questions. Key factors in successful trial design must be informed by up-to-date data on natural history, prognostic factors, clinically meaningful thresholds, and sharing available clinical trial data. The Amyloidosis Forum includes the community of patients with ATTR amyloidosis, the physicians who treat them, and the sponsors and regulators who collectively stand ready to support further studies in order to develop novel effective therapies.

Keywords: Clinical trial design; Drug development; Rare diseases; Transthyretin amyloidosis.

© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.

PubMed Disclaimer

Conflict of interest statement

Declarations

Conflict of Interest. Mathew Maurer: Grant support from NIH R01HL139671 and R01AG081582–01; grants and personal fees from Alnylam, Pfizer, Eidos, Prothena, and Ionis; and personal fees from AstraZeneca, Akcea, Intellia, and Novo-Nordisk. Prem Soman: Grant support Pfizer; Personal fees from Alnylam and BridgeBio. Adrian Hernandez: Consultant/scientific advisor to Amgen, AstraZeneca, Bayer, Bioforumis, Bristol Myer Squibb, Boehringer Engelheim, Boston Scientific, Cytokinetics, Eidos/Bridgebio, GlaxoSmith Kline, Intercept Pharmaceuticals, Intellia Therapeutics, MyoKardia, Novartis, NovoNordisk, Pfizer and TikkunLev. Research support from American Heart Association, Aires Pharmaceuticals, Amgen, American Regent, AstraZeneca, Boehringer Engelheim, Bristol-Myers Squibb, Cytokinetics, Intellia Therapeutics, Genentech, GlaxoSmithKleine, Merck, National Heart, Lung, and Blood Institute (NHLBI), Novartis, Patient-Centered Outcomes Research Institute (PCORI), Pfizer and Verily. Pablo Garcia-Pavia: Speaking fees from Pfizer, BridgeBio, Ionis Pharmaceuticals, AstraZeneca, NovoNordisk, Intellia and Alnylam Pharmaceuticals, consulting fees from Pfizer, BridgeBio, Neuroimmune, Alnylam Pharmaceuticals, AstraZeneca, NovoNordisk, ATTRalus, Intellia, General Electric and Alexion, and research/educational support to his institution from Pfizer, BridgeBio and Alnylam Pharmaceuticals. James Signorovitch: Employee of Analysis Group Inc., which provides research and consulting services to biopharma and has received consulting fees from ARC. Mazen Hanna: Served on advisory boards for Pfizer, BridgeBio, Ionis Pharmaceuticals, and Alexion Pharmaceuticals. Frederick Ruberg: Research support: NIH/NHLBI (R01 HL139671), Pfizer, Akcea/Ionis, Alnylam Consulting: ATTRalus, AstraZeneca. Sharmila Dorbala: Grant support from NIH; grants from Pfizer, ATTRalus, Siemens, Phillips; Consulting fees from Pfizer, Novo-Nordisk, BridgeBio. Jeffery Kelly: Consultant/scientific advisor to ATTRalus, George E. Hewitt Foundation for Medical Research, NeoChromosome, Pfizer, Protego, Curebound, Yumanity. Board of Directors member for George E. Hewitt Foundation for Medical Research, Protego, Yumanity. Stock in NeoChromosome, Pfizer, Protego, Yumanity. Julian Gillmore: Consultancy fees from Alnylam, Pfizer, BridgeBio, Ionis, AstraZeneca, ATTRalus, Intellia, Lycia. L J Wei, Michelle Kittleson, Dhruv Kazi, Kristen Hsu, Isabelle Lousada, Rosalyn Adigun, Preston Dunnmon have nothing to disclose.